Skip to main content


Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1338442

Assessing the Benefits and Safety Profile of Incorporating Poly ADP-ribose Polymerase (PARP) Inhibitors in the Treatment of Advanced Lung Cancer: A Thorough Systematic Review and Meta-Analysis

Provisionally accepted
  • 1 First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China
  • 2 The Second People's Hospital of Hefei, Hefei, Anhui Province, China
  • 3 Third Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China

The final, formatted version of the article will be published soon.

    Background: Poly (ADP-Ribose) Polymerase (PARP) inhibitors represent a novel class of drugs that hinder DNA repair mechanisms in tumor cells, leading to cell death. This systematic review aims to evaluate the effectiveness, safety, and potential adverse effects of PARP inhibitors (PARPi) in the management of patients with advanced lung cancer.We conducted a comprehensive search for relevant studies in PubMed, Embase, Cochrane, and We extracted primary and secondary outcome measures, including progression-free survival (PFS), overall survival (OS), and adverse events (AEs), from the identified literature for subsequent meta-analysis and systematic review.Results: This study encompassed twelve randomized controlled trials, involving 3132 patients with advanced lung cancer. In comparison to non-PARPi treatments, the administration of PARP inhibitors significantly extended overall survival (hazard ratio (HR) = 0.90, 95% CI = 0.83-0.97, p = 0.006). However, the difference in progressionfree survival did not reach statistical significance.In summary, therapies incorporating PARP inhibitors provide a degree of benefit by extending overall survival in patients with advanced lung cancer.Nonetheless, further trials are necessary to furnish additional evidence regarding the efficacy and safety of PARP inhibitors in the treatment of lung cancer.

    Keywords: polyadenosine diphosphoribose polymerase inhibitors, overall survival, Progression-free survival, lung cancer, adverse events

    Received: 16 Nov 2023; Accepted: 29 Feb 2024.

    Copyright: © 2024 Tang, Yue, Li, Han, Fei, Zhou and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Ran Wang, First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.